Compare Gilead Sciences, Inc. (GILD) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tidewater Inc — how do they compare? Gilead Sciences, Inc. trades at $150.04 (market cap $182.40B), while Tidewater Inc trades at $85.52 (market cap $4.21B). The key difference: Gilead Sciences, Inc. is far larger — about 43.3× Tidewater Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Tidewater Inc for 25 Days on average.
| GILD | TDW | |
|---|---|---|
Market Cap | $182.40B | $4.21B |
Volume | 4,469,821 | 590,005 |
Sector | Health | Energy |
52-Week High | $155.80 | $100.61 |
52-Week Low | $116.74 | $47.29 |
Typical Hold Time | 111 Days | 25 Days |
Enterprise Value | $205.46B | $4.25B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Tidewater (TDW) trades at $83.40, up 1.62% on the day, with a bullish technical signal driven by moving averages. Recent earnings showed a Q2 2026 beat but misses in Q1 and Q2 relative to expectations, while the company completed the Wilson Sons Ultratug acquisition in August 2026, signaling growth initiatives. Key financials include a P/E of 17.18 and net income margin of 18.34% for 2025, though 2026 projections indicate lower revenue and profitability.
The outlook is mixed, with analyst consensus leaning toward a buy rating and a price target of $105.50 offering upside potential, but risks include earnings volatility, competitive pressures in the energy sector, and macroeconomic headwinds affecting day rates and utilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
